Real‐world impact of once‐weekly subcutaneous semaglutide after 2 years of follow‐up: Results from a nationwide observational study in people with type 2 diabetes
Authors' conclusion
People treated with semaglutide in routine clinical practice experienced clinically relevant and sustained improvements in glycaemic control after 180, 360, 540 and 720 days, irrespective of former GLP-1RA exposure, effects which were comparable with those observed in clinical studies. These results support the use of semaglutide in routine clinical practice for the long-term management of T2D.
Study context
- Population
- People with T2D in routine clinical practice who redeemed ≥1 semaglutide prescription and had 2 years of follow-up; on-treatment cohort median age 62.0 years, diabetes duration 10.8 years, baseline HbA1c 62.0 mmol/mol4,132 on-treatment
- Participants
- 9,284 people
- Exposure
- Once-weekly subcutaneous semaglutide in GLP-1 RA-naïve vs GLP-1 RA-experienced people
- Outcome
- Mean change in HbA1c
- Follow-up
- 720 days
Methodological detailsnational registries, real-world
- National registries
- Real-world
Main finding
As reported in the abstract
| Group | Value | P |
|---|---|---|
| GLP-1RA-naïve | mean −12.6 (95% CI −13.6–-11.6) mmol/mol | P < 0.001 |
| GLP-1RA-experienced | mean −5.6 (95% CI −6.2–-5.0) mmol/mol | P < 0.001 |
Value
GLP-1RA-naïvemean −12.6 (95% CI −13.6–-11.6) mmol/mol
GLP-1RA-experiencedmean −5.6 (95% CI −6.2–-5.0) mmol/mol
P
GLP-1RA-naïveP < 0.001
GLP-1RA-experiencedP < 0.001
Observational data: associations, not effects.
Further findings
HbA1c target ≤53 mmol/mol reached · up to 2 years
Original publication
Real‐world impact of once‐weekly subcutaneous semaglutide after 2 years of follow‐up: Results from a nationwide observational study in people with type 2 diabetes. Diabetes Obes Metab. Published 9 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →